Nonremodeling Properties of Matrix Metalloproteinases
2002; Lippincott Williams & Wilkins; Volume: 90; Issue: 10 Linguagem: Inglês
10.1161/01.res.0000021398.28936.1d
ISSN1524-4571
AutoresPaul Jurasz, Ada W.Y. Chung, Anna Radomski, Marek W. Radomski,
Tópico(s)Peptidase Inhibition and Analysis
ResumoHomeCirculation ResearchVol. 90, No. 10Nonremodeling Properties of Matrix Metalloproteinases Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBNonremodeling Properties of Matrix MetalloproteinasesThe Platelet Connection Paul Jurasz, Ada W.Y. Chung, Anna Radomski and Marek W. Radomski Paul JuraszPaul Jurasz From the Department of Pharmacology, University of Alberta, Edmonton, Canada. , Ada W.Y. ChungAda W.Y. Chung From the Department of Pharmacology, University of Alberta, Edmonton, Canada. , Anna RadomskiAnna Radomski From the Department of Pharmacology, University of Alberta, Edmonton, Canada. and Marek W. RadomskiMarek W. Radomski From the Department of Pharmacology, University of Alberta, Edmonton, Canada. Originally published31 May 2002https://doi.org/10.1161/01.RES.0000021398.28936.1DCirculation Research. 2002;90:1041–1043Matrix metalloproteinases (MMPs) and their endogenous inhibitors, tissue inhibitors of metalloproteinases (TIMPs), play an important role as mediators of tissue remodeling under physiological and pathological conditions.1 Recently, a number of contributions have shown that in addition to chronic remodeling reactions, MMPs are involved in acute biological reactions associated with discrete cell signaling such as regulation of vascular reactivity,2–4 leukocyte activation,5 and platelet function.6–12 The study by Galt and colleagues, published in this issue of Circulation Research, shows that MMP-1, yet another member of the MMP family of enzymes, primes platelets for aggregation.13 They have demonstrated that the outside-in signals delivered by MMP-1 markedly increased the number of protein phosphorylated in platelets. In this respect, MMP-1 acts similar to platelet receptor agonists such as ADP, collagen, and thrombin, which are known to stimulate protein phosphorylation.14 In addition, this work provides further evidence that some biological functions of platelets are regulated by MMPs.Blood PlateletsPlatelets are small (≈2 μm in size) anucleate cell elements that are produced by fragmentation of large mother cell megakaryocytes. Although the process of platelet production (thrombopoiesis) is regulated by thrombopoietin, which controls megakaryocyte proliferation, maturation, and platelet generation, some stages of thrombopoiesis are dependent on the activity of MMP-9.15Platelets are involved in physiological hemostasis and pathological thrombosis. After accidental or pathological injury, platelets adhere to the damaged portion of the vascular wall initiating an intricate set of reactions that lead via platelet aggregation to the formation of hemostatic plug or occlusive thrombus. Complex platelet metabolic pathways are involved in regulation of platelet function (Figure). Download figureDownload PowerPointOverview of major platelet reactions and signaling pathways and how they are thought to relate to MMPs. Receptors are boxed and ligands are circled. ADP indicates adenosine diphosphate; AA, arachidonic acid; AC, adenylate cyclase; cAMP, cyclic adenosine monophosphate; cGMP, cyclic guanosine monophosphate; COX, cyclooxygenase; DAG, diacyl glycerol; GP, glycoprotein; IP3, inositol trisphosphate; MMP, matrix metalloproteinase; PL, membrane phospholipids; NO, nitric oxide; NOS, nitric oxide synthase; PLC, phospholipase C; PGI2, prostacyclin; IP-receptor, prostacyclin receptor; PAR, proteinase-activated receptor; PKA, protein kinase A; PKG, protein kinase G; TXA2, thromboxane A2; TP-receptor, thromboxane receptor; TIMP, tissue inhibitor of matrix metalloproteinases; and vWF, von Willebrand factor.Matrix Metalloproteinases and Platelet HemostasisAlthough collagenolytic activity of platelets was discovered by Chesney et al,16 as early as 1974, the molecular identity of enzymes involved remained unknown until the late 1990s. To date, four MMPs including MMP-1, MMP-2, MMP-3, and MMP-9 have been identified in human platelets.7,8,13 In resting platelets, these enzymes, similar to many cell types, are stored in the latent form. In difference to leukocytes where pro-MMP-2 and pro-MMP-9 are stored in specialized gelatinase granules,17 in platelets, pro-MMP-2 is found in the cytoplasm without an apparent association with α or dense granules.7Platelet adhesion triggered by von Willebrand factor12 and platelet aggregation by collagen, thrombin and human cancer cells all result in the liberation of both pro-MMP-1 and pro-MMP-2.6,7,10,13 The enzymes translocate to the platelet surface membrane where they appear to colocalize in areas of cell contact with β3 integrins.7,13 The translocation of pro-MMP-1 and pro-MMP-2 to the cell surface is likely to provide stimulus for enzyme activation. Interestingly, pro-MMP-2 may be activated by the classical membrane-type (MT)-MMP/TIMP-2–dependent pathway9 or by a mechanism that does not involve TIMP-2.18 A significant part of MMP-2 may be released or shed to the extracellular compartment.6,7,10 The processes of translocation and release are tightly linked to platelet activation and are downregulated by endogenous inhibitors of platelet aggregation, nitric oxide (NO), and prostacyclin I2 (PGI2).6,10What is the biological significance of this trafficking of MMPs in platelets? The experiments using molecular and pharmacological inhibitors, as well as recombinant MMP-1 and MMP-2, have shown that these enzymes may prime platelets for adhesion and aggregation.6,11–13 Moreover, MMP-2 is one of the mediators of tumor cell–induced platelet aggregation, the phenomenon that plays a role in the hematogenous dissemination of cancer.10 In contrast, MMP-9, which is expressed in platelets in lower amounts than MMP-1 or MMP-2,13 appears to counteract the platelet-aggregatory effects of MMP-2 and inhibits aggregation,8 whereas MMP-3 is devoid of any effects on aggregation.13The mechanisms of interactions of MMPs with platelets are still being elucidated. It has been demonstrated that only activated, but not latent, MMP-1 and MMP-2 stimulate platelet function suggesting that a limited proteolysis might underlie the platelet activator actions of these compounds.6,13 The actions of MMP-2 may involve modification of major platelet receptor glycoproteins GP Ib12 and GP IIb/IIIa11 or their ligands, whereas those of MMP-1 are based upon stimulation of tyrosine phosphorylation and clustering of β3 integrins to focal adhesion points.13 Whether MMP-1 and/or other MMPs modulate tyrosine phosphorylation via interactions with specific platelet receptors remains to be studied. Although the actions of MMPs on platelets may not require the intermediate formation of cellular mediators such as thromboxane A2 and ADP,6,10,12 MMP-2 crosstalks with other platelet agonists including proteinase-activated receptor (PAR) peptides.19Of four known endogenous inhibitors of MMPs,20 only TIMP-1 and TIMP-4 proteins appear to be expressed in measurable amounts in platelets, and TIMP-4 may be associated with MMP-2.18 However, it is likely that TIMP-2 that is expressed in high amounts in the vasculature21 also contributes to the regulation of MMP actions on platelets in vivo.Pathological and Pharmacological SignificancePlatelet thrombosis may complicate the course of vascular disorders including atherosclerosis and diabetes. The structural disruption of the vascular wall, plaque rupture, and thrombosis are the pathological hallmarks of the coronary artery disease and myocardial infarction. MMPs are overexpressed at the site of human atheroma, and they may cause the matrix weakening and plaque rupture.22 Moreover, the release of MMP-2 exaggerates myocardial ischemia-reperfusion injury.23 Therefore, it is likely that the release of MMP-1, MMP-2, and MMP-9 from platelets, the vessel wall, myocardium, and monocytes6–9,13,24 may contribute to the thrombotic complications of atherosclerotic plaque rupture. The release of MMP-2 may also play a role in the thrombotic and inflammatory complications of the use of extracorporeal circulation25,26 and contribute to the hematogenous cancer metastasis.10Pharmacological studies have shown that human recombinant TIMP-2 and TIMP-4, but not TIMP-1, have the ability to inhibit platelet activation.6,9,18 In addition to endogenous inhibitors, a number of structurally unrelated chemical inhibitors of MMPs reduce platelet adhesion and aggregation in vitro.6,9–13 Unfortunately most, if not all, chemical inhibitors of MMPs, although specifically inhibit the MMP family of enzymes, show a low level of selectivity toward individual members of this family. This relative lack of selectivity might be one of the reasons behind the lack of effectiveness of chemical inhibitors in the treatment of cancer.27 It is also important to note that not all pathways of platelet activation are MMP-dependent. For example, platelet aggregation induced by PAR-4 agonist, AYPGKF, is MMP-independent.19 On the other hand, MMP inhibitors may decrease a part of platelet activation that is not sensitive to inhibition with aspirin or ADP antagonists6,10,12 and potentially stabilize the atherosclerotic plaque. Therefore, the concept of selective pharmacological inhibition of MMPs to reduce thrombotic complications of vascular disorders is worth considering.6 Interestingly, PGI2 and NO both decrease activation-induced release of MMP-2.6,10 Moreover, m7E3 (ReoPro, abciximab), a GP IIb/IIIa receptor antagonist, reduced the release of MMPs and attenuated the vascular injury in rats.28 This ability to modulate MMP release from platelets and the vascular wall is likely to contribute to the pharmacological profile of PGI2, NO, and m7E3 as potent antiplatelet agents.ConclusionsOver the past few years, MMPs have emerged as a novel system that regulates platelet function. Understanding the biological effects of MMPs on the vascular hemostasis and thrombosis may have basic, clinical, and therapeutic significance.The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.The authors' work is supported by the Canadian Institutes of Health Research.FootnotesCorrespondence to Dr Marek W. Radomski, Department of Pharmacology, University of Alberta, Edmonton, Alberta, 9-50 Medical Sciences Bldg, T6G 2H7, Canada. E-mail [email protected] References 1 Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behaviour. Annu Rev Cell Dev Biol. 2001; 17: 463–516.CrossrefMedlineGoogle Scholar2 Fernandez-Patron C, Radomski MW, Davidge SM. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res. 1999; 85: 906–911.CrossrefMedlineGoogle Scholar3 Fernandez-Patron C, Stewart K, Zhang Y, Koivunen E, Radomski MW, Davidge S. Vascular matrix metalloproteinase-2–dependent cleavage of calcitonin-gene related peptide promotes vasoconstriction. Circ Res. 2000; 87: 670–676.CrossrefMedlineGoogle Scholar4 Fernandez-Patron C, Radomski MW, Davidge S. Role of matrix metalloproteinase-2 in thrombin-induced vasorelaxation of rat mesenteric arteries. Am J Physiol. 2000; 278: H1473–H1479.CrossrefMedlineGoogle Scholar5 McQuibban GA, Gong JH, Tam EM, McCulloch CA, Clark-Lewis I, Overall CM. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science. 2000; 289: 1202–1206.CrossrefMedlineGoogle Scholar6 Sawicki G, Salas E, Murat J, Miszta-Lane H, Radomski MW. Release of gelatinase A from human platelets mediates aggregation. Nature. 1997; 386: 616–619.CrossrefMedlineGoogle Scholar7 Sawicki G, Sanders ES, Salas E, Wozniak M, Rodrigo J, Radomski MW. Localization and translocation of MMP-2 during aggregation of human platelets. Thromb Haemost. 1998; 80: 836–839.CrossrefMedlineGoogle Scholar8 Fernandez-Patron C, Martinez-Cuesta MA, Salas E, Sawicki G, Wozniak M, Radomski MW, Davidge ST. Differential regulation of platelet aggregation by matrix metalloproteinase-9 and -2. Thromb Haemost. 1999; 82: 1730–1735.CrossrefMedlineGoogle Scholar9 Kazes I, Elalamy I, Sraer J-D, Hatmi M, Nguyen G. Platelet release of trimolecular complex components MT1MMP/TIMP2/MMP2: involvement in MMP2 activation and platelet aggregation. Blood. 2000; 6: 3064–3069.Google Scholar10 Jurasz P, Sawicki G, Duszyk M, Sawicka J, Miranda C, Mayers I, Radomski MW. Matrix metalloproteinase-2 in tumour-cell induced platelet aggregation: regulation by NO. Cancer Res. 2001; 61: 376–382.MedlineGoogle Scholar11 Martinez A, Salas E, Radomski A, Radomski MW. Matrix metalloproteinase-2 in platelet adhesion to fibrinogen: interactions with nitric oxide. Med Sci Monit. 2001; 7: 646–651.MedlineGoogle Scholar12 Radomski A, Stewart MJ, Jurasz P, Radomski MW. Pharmacological characteristics of solid-phase von Willebrand factor in human platelets. Br J Pharmacol. 2001; 134: 1013–1020.CrossrefMedlineGoogle Scholar13 Galt SW, Lindemann S, Allen L, Medd DJ, Falk JM, McIntyre TM, Prescott SM, Kraiss LW, Zimmerman GA, Weyrich AS. Outside-in signals delivered by matrix metalloproteinase-1 regulate platelet function. Circ Res. 2002; 90: 1093–1099.LinkGoogle Scholar14 Clark EL, Shattil SJ, Brugge JS. Regulation of protein tyrosine kinases in platelets. Trends Biochem Sci. 1994; 19: 464–469.CrossrefMedlineGoogle Scholar15 Lane WJ, Dias S, Hattori K, Heissig B, Choy M, Rabbany SY, Wood J, Moore MAS, Rafii S. Stromal-derived factor-1 induced megakaryocyte migration and platelet production is dependent on matrix metalloproteinases. Blood. 2000; 96: 4152–4159.CrossrefMedlineGoogle Scholar16 Chesney CM, Harper E, Colman RW. Human platelet collagenase. J Clin Invest. 1974; 53: 1647–1654.CrossrefMedlineGoogle Scholar17 Borregaard N, Lollike K, Kjeldsen L, Sengelov H, Bastholm L, Nielsen MH, Bainton DF. Human neutrophil granules and secretory vesicles. Eur J Haematol. 1993; 51: 187–198.MedlineGoogle Scholar18 Jurasz P, Radomski A, Sawicki G, Duszyk M, Radomski MW. MMP-2 and TIMP-4 regulate tumor cell induced platelet aggregation. Paper presented at: International Congress on Membrane-Bound Proteolytic Enzymes and Cancer;May 19–21, 2001; Palermo, Italy.Google Scholar19 Chung AWY, Jurasz P, Hollenberg MD, Radomski MW. Mechanisms of action of proteinase-activated receptor agonists on human platelets. Br J Pharmacol. 2002; 135: 1123–1132.CrossrefMedlineGoogle Scholar20 Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta. 2000; 1477: 267–283.CrossrefMedlineGoogle Scholar21 Kranzhofer A, Baker AH, George SJ, Newby AC. Expression of tissue inhibitor of metalloproteinase-1, -2, and -3 during neointima formation in organ cultures of human saphenous vein. Arterioscler Thromb Vasc Biol. 1999; 19: 255–265.CrossrefMedlineGoogle Scholar22 Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002; 90: 251–262.LinkGoogle Scholar23 Cheung P-Y, Sawicki G, Wozniak M, Wang W, Radomski MW, Schulz R. Matrix metalloproteinase-2 contributes to the ischemia-reperfusion injury in the heart. Circulation. 2000; 101: 1833–1839.CrossrefMedlineGoogle Scholar24 Galt SW, Lindemann S, Medd D, Allen LL, Kraiss LW, Harris ES, Prescott SM, McIntyre TM, Weyrich AS, Zimmerman GA. Differential regulation of matrix metalloproteinases-9 in monocytes adherent to collagen and platelets. Circ Res. 2001; 89: 509–516.CrossrefMedlineGoogle Scholar25 Cheung P-Y, Sawicki G, Salas E, Etches PC, Schulz R, Radomski MW. The mechanisms of platelet dysfunction during extracorporeal membrane oxygenation in acutely ill neonates. Crit Care Med. 2000; 28: 2584–2590.CrossrefMedlineGoogle Scholar26 Mayers I, Hurst T, Puttagunta L, Radomski A, Johnson D, Sawicki G, Radomski MW. Cardiac surgery increases the activity of matrix metalloproteinases and nitric oxide synthase in humans. J Thorac Cardiovasc Surg. 2001; 122: 746–752.CrossrefMedlineGoogle Scholar27 Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinases inhibitors in cancer treatment. Oncogene. 2000; 19: 6642–6650.CrossrefMedlineGoogle Scholar28 Bendeck MP, Nakada MT. The β3 integrin antagonist m7E3 reduces matrix metalloproteinases activity and smooth muscle cell migration. J Vasc Res. 2001; 38: 590–599.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Bassiouni W, Ali M and Schulz R (2021) Multifunctional intracellular matrix metalloproteinases: implications in disease, The FEBS Journal, 10.1111/febs.15701, 288:24, (7162-7182), Online publication date: 1-Dec-2021. Li S, Mohamedi A, Senkowsky J, Nair A and Tang L (2020) Imaging in Chronic Wound Diagnostics, Advances in Wound Care, 10.1089/wound.2019.0967, 9:5, (245-263), Online publication date: 1-May-2020. Takagi S, Tsukamoto S, Park J, Johnson K, Kawano Y, Moschetta M, Liu C, Mishima Y, Kokubun K, Manier S, Salem K, Huynh D, Sacco A, Forward J, Roccaro A, Battinelli E and Ghobrial I (2018) Platelets Enhance Multiple Myeloma Progression via IL-1β Upregulation, Clinical Cancer Research, 10.1158/1078-0432.CCR-17-2003, 24:10, (2430-2439), Online publication date: 15-May-2018. Jobin P, Butler G and Overall C (2017) New intracellular activities of matrix metalloproteinases shine in the moonlight, Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 10.1016/j.bbamcr.2017.05.013, 1864:11, (2043-2055), Online publication date: 1-Nov-2017. Zhang Q, Liu H, Zhu Q, Zhan P, Zhu S, Zhang J, Lv T and Song Y (2017) Patterns and functional implications of platelets upon tumor "education", The International Journal of Biochemistry & Cell Biology, 10.1016/j.biocel.2017.07.018, 90, (68-80), Online publication date: 1-Sep-2017. Chang M (2016) Restructuring of the extracellular matrix in diabetic wounds and healing: A perspective, Pharmacological Research, 10.1016/j.phrs.2016.03.008, 107, (243-248), Online publication date: 1-May-2016. Hüfner K, Koudouovoh-Tripp P, Kandler C, Hochstrasser T, Malik P, Giesinger J, Semenitz B, Humpel C and Sperner-Unterweger B (2015) Differential changes in platelet reactivity induced by acute physical compared to persistent mental stress, Physiology & Behavior, 10.1016/j.physbeh.2015.07.021, 151, (284-291), Online publication date: 1-Nov-2015. Gul M, Uyarel H, Akgul O, Uslu N, Yildirim A, Eksik A, Aksu H, Ozal E, Pusuroglu H, Erol M and Bakir I (2012) Hematologic and Clinical Parameters After Transcatheter Aortic Valve Implantation (TAVI) in Patients With Severe Aortic Stenosis, Clinical and Applied Thrombosis/Hemostasis, 10.1177/1076029612462762, 20:3, (304-310), Online publication date: 1-Apr-2014. Roy S, Chakraborti T, Shaikh S, Chowdhury A and Chakraborti S (2014) Matrix Metalloprotease-2 in the Development and Progression of Cardiovascular Diseases Role of Proteases in Cellular Dysfunction, 10.1007/978-1-4614-9099-9_19, (351-364), . Soslau G, Mason C, Lynch S, Benjamin J, Ashak D, Prakash J, Moore A, Bagsiyao P, Albert T, Mathew L and Jost M (2017) Intracellular matrix metalloproteinase-2 (MMP-2) regulates human platelet activation via hydrolysis of talin, Thrombosis and Haemostasis, 10.1160/TH13-03-0248, 111:01, (140-153), . Inanc M, Duran A, Karaca H, Berk V, Bozkurt O, Ozaslan E and Ozkan M (2014) Haematologic Parameters in Metastatic Colorectal Cancer Patients Treated with Capecitabine Combination Therapy, Asian Pacific Journal of Cancer Prevention, 10.7314/APJCP.2014.15.1.253, 15:1, (253-256), Online publication date: 15-Jan-2014. Battinelli E, Markens B, Kulenthirarajan R, Machlus K, Flaumenhaft R and Italiano J (2014) Anticoagulation inhibits tumor cell–mediated release of platelet angiogenic proteins and diminishes platelet angiogenic response, Blood, 10.1182/blood-2013-02-485011, 123:1, (101-112), Online publication date: 2-Jan-2014. Thomas A (2013) Metalloproteinases in Acute Venous Occlusion Inflammatory Response in Cardiovascular Surgery, 10.1007/978-1-4471-4429-8_19, (141-151), . Pandith H, Zhang X, Liggett J, Min K, Gritsanapan W and Baek S (2013) Hemostatic and Wound Healing Properties of Chromolaena odorata Leaf Extract , ISRN Dermatology, 10.1155/2013/168269, 2013, (1-8), Online publication date: 1-Aug-2013. Radziwon-Balicka A, Moncada de la Rosa C and Jurasz P (2012) Platelet-associated angiogenesis regulating factors: a pharmacological perspective, Canadian Journal of Physiology and Pharmacology, 10.1139/y2012-036, 90:6, (679-688), Online publication date: 1-Jun-2012. Buergy D, Wenz F, Groden C and Brockmann M (2012) Tumor-platelet interaction in solid tumors, International Journal of Cancer, 10.1002/ijc.27441, 130:12, (2747-2760), Online publication date: 15-Jun-2012. Wrzyszcz A and Wozniak M (2012) On the origin of matrix metalloproteinase-2 and -9 in blood platelets, Platelets, 10.3109/09537104.2012.682103, 23:6, (467-474), Online publication date: 1-Sep-2012. Battinelli E, Markens B and Italiano J (2011) Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis, Blood, 10.1182/blood-2011-02-334524, 118:5, (1359-1369), Online publication date: 4-Aug-2011. Brockmann M, Bender B, Plaxina E, Nolte I, Erber R, Lamszus K, Groden C and Schilling L (2011) Differential effects of tumor–platelet interaction in vitro and in vivo in glioblastoma, Journal of Neuro-Oncology, 10.1007/s11060-011-0560-2, 105:1, (45-56), Online publication date: 1-Oct-2011. Vasina E, Cauwenberghs S, Feijge M, Heemskerk J, Weber C and Koenen R (2011) Microparticles from apoptotic platelets promote resident macrophage differentiation, Cell Death & Disease, 10.1038/cddis.2011.94, 2:9, (e211-e211), Online publication date: 1-Sep-2011. CHOI W, JEON O and KIM D (2010) CD40 ligand shedding is regulated by interaction between matrix metalloproteinase-2 and platelet integrin α IIb β 3 , Journal of Thrombosis and Haemostasis, 10.1111/j.1538-7836.2010.03837.x, 8:6, (1364-1371), Online publication date: 1-Jun-2010. Sucu M, Davutoglu V, Sari I, Ozer O and Aksoy M (2009) Relationship Between Platelet Indices and Aortic Valve Sclerosis, Clinical and Applied Thrombosis/Hemostasis, 10.1177/1076029609338046, 16:5, (563-567), Online publication date: 1-Oct-2010. Folkman J and Italiano J (2009) Angiogenesis Oncology of Infancy and Childhood, 10.1016/B978-1-4160-3431-5.00002-9, (27-40), . Mannello F (2008) Serum or Plasma Samples?, Arteriosclerosis, Thrombosis, and Vascular Biology, 28:4, (611-614), Online publication date: 1-Apr-2008. CHOI W, JEON O, KIM H and KIM D (2008) MMP-2 regulates human platelet activation by interacting with integrin α IIb β 3 , Journal of Thrombosis and Haemostasis, 10.1111/j.1538-7836.2007.02871.x, 6:3, (517-523), Online publication date: 1-Mar-2008. Nolte I, Przibylla H, Bostel T, Groden C and Brockmann M (2008) Tumor–platelet interactions: Glioblastoma growth is accompanied by increasing platelet counts, Clinical Neurology and Neurosurgery, 10.1016/j.clineuro.2007.12.008, 110:4, (339-342), Online publication date: 1-Apr-2008. Accorsi-Mendonça T, Paiva K, Zambuzzi W, Cestari T, Lara V, Sogayar M, Taga R and Granjeiro J (2007) Expression of matrix metalloproteinases-2 and -9 and RECK during alveolar bone regeneration in rat, Journal of Molecular Histology, 10.1007/s10735-007-9152-z, 39:2, (201-208), Online publication date: 1-Apr-2008. Chung A, Hsiang Y, Matzke L, McManus B, van Breemen C and Okon E (2006) Reduced Expression of Vascular Endothelial Growth Factor Paralleled With the Increased Angiostatin Expression Resulting From the Upregulated Activities of Matrix Metalloproteinase-2 and -9 in Human Type 2 Diabetic Arterial Vasculature, Circulation Research, 99:2, (140-148), Online publication date: 21-Jul-2006. JURASZ P, SANTOS-MARTINEZ M, RADOMSKA A and RADOMSKI M (2006) Generation of platelet angiostatin mediated by urokinase plasminogen activator: effects on angiogenesis, Journal of Thrombosis and Haemostasis, 10.1111/j.1538-7836.2006.01878.x, 4:5, (1095-1106), Online publication date: 1-May-2006. Kopp H, Hooper A, Broekman M, Avecilla S, Petit I, Luo M, Milde T, Ramos C, Zhang F, Kopp T, Bornstein P, Jin D, Marcus A and Rafii S (2006) Thrombospondins deployed by thrombopoietic cells determine angiogenic switch and extent of revascularization, Journal of Clinical Investigation, 10.1172/JCI29314, 116:12, (3277-3291), Online publication date: 1-Dec-2006. Alonso-Escolano D, Medina C, Cieslik K, Radomski A, Jurasz P, Santos-Martínez M, Jiffar T, Ruvolo P and Radomski M (2006) Protein Kinase Cδ Mediates Platelet-Induced Breast Cancer Cell Invasion, Journal of Pharmacology and Experimental Therapeutics, 10.1124/jpet.106.103358, 318:1, (373-380), Online publication date: 1-Jul-2006. Kisucka J, Butterfield C, Duda D, Eichenberger S, Saffaripour S, Ware J, Ruggeri Z, Jain R, Folkman J and Wagner D (2006) Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage, Proceedings of the National Academy of Sciences, 10.1073/pnas.0510412103, 103:4, (855-860), Online publication date: 24-Jan-2006. Radomski A, Jurasz P, Alonso-Escolano D, Drews M, Morandi M, Malinski T and Radomski M (2009) Nanoparticle-induced platelet aggregation and vascular thrombosis, British Journal of Pharmacology, 10.1038/sj.bjp.0706386, 146:6, (882-893), Online publication date: 1-Nov-2005. Aktas B, Pozgajova M, Bergmeier W, Sunnarborg S, Offermanns S, Lee D, Wagner D and Nieswandt B (2005) Aspirin Induces Platelet Receptor Shedding via ADAM17 (TACE), Journal of Biological Chemistry, 10.1074/jbc.M507762200, 280:48, (39716-39722), Online publication date: 1-Dec-2005. Bergmeier W, Piffath C, Cheng G, Dole V, Zhang Y, von Andrian U and Wagner D (2004) Tumor Necrosis Factor-α–Converting Enzyme (ADAM17) Mediates GPIbα Shedding From Platelets In Vitro and In Vivo, Circulation Research, 95:7, (677-683), Online publication date: 1-Oct-2004. Alonso-Escolano D, Strongin A, Chung A, Deryugina E and Radomski M (2009) Membrane type-1 matrix metalloproteinase stimulates tumour cell-induced platelet aggregation: role of receptor glycoproteins, British Journal of Pharmacology, 10.1038/sj.bjp.0705606, 141:2, (241-252), Online publication date: 1-Jan-2004. Chung A, Radomski A, Alonso-Escolano D, Jurasz P, Stewart M, Malinski T and Radomski M (2009) Platelet-leukocyte aggregation induced by PAR agonists: regulation by nitric oxide and matrix metalloproteinases, British Journal of Pharmacology, 10.1038/sj.bjp.0705997, 143:7, (845-855), Online publication date: 1-Dec-2004. Jurasz P, Alonso-Escolano D and Radomski M (2009) Platelet-cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation, British Journal of Pharmacology, 10.1038/sj.bjp.0706013, 143:7, (819-826), Online publication date: 1-Dec-2004. Heo J, Kim S, Lee K, Kim E, Chu C and Nam J (2003) Increase in Plasma Matrix Metalloproteinase-9 in Acute Stroke Patients With Thrombolysis Failure, Stroke, 34:6, (e48-e50), Online publication date: 1-Jun-2003. Cedro K, Radomski A, Radomski M, Ruźyłło W and Herbaczyńska-Cedro K (2003) Release of matrix metalloproteinase-9 during balloon angioplasty in patients with stable angina., International Journal of Cardiology, 10.1016/S0167-5273(03)00092-5, 92:2-3, (177-180), Online publication date: 1-Dec-2003. Jurasz P, Alonso D, Castro-Blanco S, Murad F and Radomski M (2003) Generation and role of angiostatin in human platelets, Blood, 10.1182/blood-2003-02-0378, 102:9, (3217-3223), Online publication date: 1-Nov-2003. Radomski A, Jurasz P, Sanders E, Overall C, Bigg H, Edwards D and Radomski M (2009) Identification, regulation and role of tissue inhibitor of metalloproteinases-4 (TIMP-4) in human platelets, British Journal of Pharmacology, 10.1038/sj.bjp.0704936, 137:8, (1330-1338), Online publication date: 1-Dec-2002. Mutlu A, Allen D, Freedman J and Leytin V (2007) The level of matrix metalloproteinase-2 in donor plasma strongly correlates with post-transfusion recovery of stored platelet concentrates, Vox Sanguinis, 10.1111/j.1423-0410.2007.01001.x, 0:0, (071120025214001-???) Strasenburg W, Jóźwicki J, Durślewicz J, Kuffel B, Kulczyk M, Kowalewski A, Grzanka D, Drewa T and Adamowicz J (2022) Tumor Cell-Induced Platelet Aggregation as an Emerging Therapeutic Target for Cancer Therapy, Frontiers in Oncology, 10.3389/fonc.2022.909767, 12 Lesyk G and Jurasz P (2019) Advances in Platelet Subpopulation Research, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2019.00138, 6 May 31, 2002Vol 90, Issue 10 Advertisement Article InformationMetrics https://doi.org/10.1161/01.RES.0000021398.28936.1DPMID: 12039792 Originally publishedMay 31, 2002 Keywordstissue inhibitor of metalloproteinasesplatelet functionmatrix metalloproteinasesPDF download Advertisement
Referência(s)